Atherosclerotic plaque destabilization: Mechanisms, models, and therapeutic strategies

Circulation Research

Volumn 114, Issue 1, 2014, Pages 214-226

  Silvestre Roig, Carlos ^a   De Winther, Menno P ^a   Weber, Christian ^b,c   Daemen, Mat J ^a   Lutgens, Esther ^a,b   Soehnlein, Oliver ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

atherosclerosis; efferocytosis; macrophages; necrotic core; neutrophils

Indexed keywords

PROTEINASE; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CLINICAL STUDY; ENZYME ACTIVITY; HUMAN; INFLAMMATORY CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84892935256     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.302355     Document Type: Review

References (125)

1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
2. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34:719-728.
3. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075-1080.
4. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol. 2003;23:1553-1558.
5. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med. 2006;203:239-250.
6. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and proinfammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-defcient mice. Circulation. 2013;127:1028-1039.
7. den Dekker WK, Tempel D, Bot I, Biessen EA, Joosten LA, Netea MG, van der Meer JW, Cheng C, Duckers HJ. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol. 2012;32:1960-1969.
8. Williams H, Johnson JL, Jackson CL, White SJ, George SJ. MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res. 2010;87:137-146.
9. von Wnuck Lipinski K, Keul P, Ferri N, Lucke S, Heusch G, Fischer JW, Levkau B. Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ Res. 2006;98:1490-1497.
10. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
11. Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ, Lesnik P. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation. 2009;119:1795-1804.
12. Tabas I. Consequences and therapeutic implications of macrophage apop-tosis in atherosclerosis: the importance of lesion stage and phagocytic ef-fciency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
13. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259-1268.
14. Thorp E, Li G, Seimon TA, Kuriakose G, Ron D, Tabas I. Reduced apopto-sis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/-and Ldlr-/-mice lacking CHOP. Cell Metab. 2009;9:474-481.
15. Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K, Asada Y, Okada K, Ishibashi-Ueda H, Gabbiani G, Bochaton-Piallat ML, Mochizuki N, Kitakaze M. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 2007;116:1226-1233.
16. Thorp E, Li Y, Bao L, Yao PM, Kuriakose G, Rong J, Fisher EA, Tabas I. Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/-mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc Biol. 2009;29:169-172.
17. Lim WS, Timmins JM, Seimon TA, Sadler A, Kolodgie FD, Virmani R, Tabas I. Signal transducer and activator of transcription-1 is critical for apop-tosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation. 2008;117:940-951.
18. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA. 2006;103:19794-19799.
19. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006;291:E275-E281.
20. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplas-mic reticulum stress. Cell Metab. 2010;12:467-482.
21. Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, Tabas IA. Macrophage defciency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest. 2009;119:886-898.
22. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, Robbins J, Martinez J, Tabas I. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 2012;15:545-553.
23. Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of infammation: an integrated view. EMBO Mol Med. 2013;5:661-674.
24. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1256-1261.
25. Ravichandran KS. Beginnings of a good apoptotic meal: the fnd-me and eat-me signaling pathways. Immunity. 2011;35:445-455.
26. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipopro-tein receptor-defcient mice. Circulation. 2007;115:501-508.
27. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL. Defciency of the long pentraxin PTX3 promotes vascular infammation and atherosclerosis. Circulation. 2009;120:699-708.
28. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-defcient mice. Circulation. 2009;120:417-426.
29. Moura R, Tjwa M, Vandervoort P, Van Kerckhoven S, Holvoet P, Hoylaerts MF. Thrombospondin-1 defciency accelerates atherosclerotic plaque maturation in ApoE-/-mice. Circ Res. 2008;103:1181-1189.
30. Ait-Oufella H, Kinugawa K, Zoll J, et al. Lactadherin defciency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007;115:2168-2177.
31. Lutgens E, Tjwa M, Garcia de Frutos P, Wijnands E, Beckers L, Dahlbäck B, Daemen MJ, Carmeliet P, Moons L. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. J Pathol. 2008;216:55-63.
32. Li S, Sun Y, Liang C P, et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fsh oil diet. Circ Res. 2009;105:1072-1082.
33. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis effciency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol. 2008;28:1421-1428.
34. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein ki-nase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 2011;286:33335-33344.
35. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109:1026-1033.
36. Driscoll WS, Vaisar T, Tang J, Wilson CL, Raines EW. Macrophage ADAM17 defciency augments CD36-dependent apoptotic cell uptake and the linked anti-infammatory phenotype. Circ Res. 2013;113:52-61.
37. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol. 2012;56:232-244.
38. Peeters W, Moll FL, Vink A, van der Spek PJ, de Kleijn DP, de Vries J P, Verheijen JH, Newby AC, Pasterkamp G. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J. 2011;32:2314-2325.
39. Scholtes VP, Johnson JL, Jenkins N, Sala-Newby GB, de Vries JP, de Borst GJ, de Kleijn DP, Moll FL, Pasterkamp G, Newby AC. Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy. J Am Heart Assoc. 2012;1:e001040.
40. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA. 2005;102:15575-15580.
41. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-defcient mice. J Clin Invest. 2006;116:59-69.
42. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009;105:921-929.
43. Quillard T, Tesmenitsky Y, Croce K, Travers R, Shvartz E, Koskinas KC, Sukhova GK, Aikawa E, Aikawa M, Libby P. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:2464-2472.
44. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, Vink A, de Kleijn DP. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2010;30:1842-1848.
45. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012;122:70-79.
46. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 defciency on atherosclerotic lesion formation in apoE-defcient mice. Arterioscler Thromb Vasc Biol. 2006;26:1120-1125.
47. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-349.
48. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, Channon KM. Coronary artery su-peroxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26:333-339.
49. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429-1435.
50. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation. 2004;109:520-525.
51. Terashima M, Ohashi Y, Azumi H, Otsui K, Kaneda H, Awano K, Kobayashi S, Honjo T, Suzuki T, Maeda K, Yokoyama M, Inoue N. Impact of NAD(P) H oxidase-derived reactive oxygen species on coronary arterial remodeling: a comparative intravascular ultrasound and histochemical analysis of atherosclerotic lesions. Circ Cardiovasc Interv. 2009;2:196-204.
52. Gray S P, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013;127:1888-1902.
53. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001;108:1513-1522.
54. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T. Vascular effects following homozygous disruption of p47(phox): An essential component of NADPH oxidase. Circulation. 2000;101:1234-1236.
55. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, Van der Spek PJ, de Vries JP, Seldenrijk KA, De Bruin PC, Vink A, Velema E, de Kleijn DP, Pasterkamp G. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation. 2010;121:1941-1950.
56. Sluimer JC, Kolodgie FD, Bijnens A P, Maxfeld K, Pacheco E, Kutys B, Duimel H, Frederik PM, van Hinsbergh VW, Virmani R, Daemen MJ. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009;53:1517-1527.
57. Eriksson EE. Intravital microscopy on atherosclerosis in apolipoprotein e-defcient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation. 2011;124:2129-2138.
58. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-defcient mice. Circulation. 2007;115:2516-2525.
59. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 2001;7:1123-1127.
60. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51:1258-1265.
61. Lucerna M, Zernecke A, de Nooijer R, de Jager SC, Bot I, van der Lans C, Kholova I, Liehn EA, van Berkel TJ, Yla-Herttuala S, Weber C, Biessen EA. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood. 2007;109:122-129.
62. Cheng C, Tempel D, Den Dekker WK, Haasdijk R, Chrif I, Bos FL, Wagtmans K, van de Kamp EH, Blonden L, Biessen EA, Moll F, Pasterkamp G, Serruys PW, Schulte-Merker S, Duckers HJ. Ets2 determines the infammatory state of endothelial cells in advanced atherosclerotic lesions. Circ Res. 2011;109:382-395.
63. Fukuda D, Aikawa E, Swirski FK, Novobrantseva TI, Kotelianski V, Gorgun CZ, Chudnovskiy A, Yamazaki H, Croce K, Weissleder R, Aster JC, Hotamisligil GS, Yagita H, Aikawa M. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci USA. 2012;109:E1868-E1877.
64. Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007;27:705-713.
65. von der Thüsen JH, van Berkel TJ, Biessen EA. Induction of rapid ath-erogenesis by perivascular carotid collar placement in apolipoprotein E-defcient and low-density lipoprotein receptor-defcient mice. Circulation. 2001;103:1164-1170.
66. von der Thüsen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA. Induction of atherosclerotic plaque rupture in apolipoprotein E-/-mice after adenovirus-mediated transfer of p53. Circulation. 2002;105:2064-2070.
67. de Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340-346.
68. Borissoff JI, Otten JJ, Heeneman S, et al. Genetic and pharmacological modifcations of thrombin formation in apolipoprotein e-defcient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One. 2013;8:e55784.
69. Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Shibata T, Sato K, Iguchi A. A simple method of plaque rupture induction in apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 2006;26:1304-1309.
70. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fuid shear stress. Circulation. 2006;113:2744-2753.
71. Jin SX, Shen LH, Nie P, Yuan W, Hu LH, Li DD, Chen XJ, Zhang XK, He B. Endogenous renovascular hypertension combined with low shear stress induces plaque rupture in apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 2012;32:2372-2379.
72. Chen YC, Bui AV, Diesch J, Manasseh R, Hausding C, Rivera J, Haviv I, Agrotis A, Htun NM, Jowett J, Hagemeyer CE, Hannan RD, Bobik A, Peter K. A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and mi-croRNA expression profling. Circ Res. 2013;113:252-265.
73. Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1104-1115.
74. Johnstone MT, Perez AS, Nasser I, Stewart R, Vaidya A, Al Ammary F, Schmidt B, Horowitz G, Dolgoff J, Hamilton J, Quist WC. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation. 2004;110:2060-2065.
75. Thim T, Hagensen MK, Drouet L, Bal Dit Sollier C, Bonneau M, Granada JF, Nielsen LB, Paaske WP, Bøtker HE, Falk E. Familial hypercholester-olaemic downsized pig with human-like coronary atherosclerosis: a model for preclinical studies. EuroIntervention. 2010;6:261-268.
76. Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, Malik S, Fuster V, Finn AV. Histopathologic characteristics of atherosclerotic coronary disease and implications of the fndings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61:1041-1051.
77. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, Waxman S, Domanski MJ, Srinivas PR, Narula J. Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. J Am Coll Cardiol Cardiovasc Imaging. 2012;5:941-955.
78. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso S P, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235.
79. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111:231-244.
80. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of mac-rophages in infammatory atherosclerosis. Circulation. 2008;117:379-387.
81. Majmudar MD, Yoo J, Keliher EJ, Truelove JJ, Iwamoto Y, Sena B, Dutta P, Borodovsky A, Fitzgerald K, Di Carli MF, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013;112:755-761.
82. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, Hoffmann U, Brady TJ, Tawakol A. Distribution of infammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5:69-77.
83. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol. 2012;32:e36-e48.
84. Hyafl F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, Lancelot E, Corot C, Fuster V, Galis ZS, Feldman LJ, Fayad ZA. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metallopro-teinases. Eur Heart J. 2011;32:1561-1571.
85. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, Shi GP, Libby P, Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fuorescence sensor. Circulation. 2007;115:2292-2298.
86. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, Narula J. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472-1473.
87. Briley-Saebo KC, Nguyen TH, Saeboe AM, et al. In vivo detection of oxidation-specifc epitopes in atherosclerotic lesions using biocompat-ible manganese molecular magnetic imaging probes. J Am Coll Cardiol. 2012;59:616-626.
88. Ronald JA, Chen JW, Chen Y, Hamilton AM, Rodriguez E, Reynolds F, Hegele RA, Rogers KA, Querol M, Bogdanov A, Weissleder R, Rutt BK. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxi-dase identifes active infammation in experimental rabbit atherosclerotic plaques. Circulation. 2009;120:592-599.
89. Giannarelli C, Ibanez B, Cimmino G, Garcia Ruiz JM, Faita F, Bianchini E, Zafar MU, Fuster V, Garcia MJ, Badimon JJ. Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:1256-1264.
90. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60:1715-1721.
91. Schunkert H, König IR, Kathiresan S, et al; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifes 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-338.
92. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifes new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33
93. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, Ridker PM. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-637.
94. Ripatti S, Tikkanen E, Orho-Melander M, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393-1400.
95. Perk J, De Backer G, Gohlke H, et al; Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The ffth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19:585-667.
96. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013.
97. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M, Egashira K, Kataoka Y, Imaizumi T. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res. 2007;101:348-356.
98. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl H, Soehnlein O, Binder CJ. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4:1072-1086.
99. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864-871.
100. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fbrinogen: A phase iib randomized, placebo-controlled trial. Circulation. 2012;126:2739-2748
101. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol. 2008;28:1090-1096.
102. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, Baldelli F, Fiorucci S. Effcacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013;127:2114-2124.
103. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in infammatory monocytes in mice. Nat Biotechnol. 2011;29:1005-1010.
104. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M; MLN1202 Study Group. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte che-moattractant protein-1 promoter region. Am J Cardiol. 2011;107:906-911.
105. Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, Perez N, Barateau V, Nilsson J, Tedgui A, Mallat Z. Regulatory T-cell response to apolipopro-tein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:605-612.
106. Mundkur L, Mukhopadhyay R, Samson S, Varma M, Kale D, Chen D, Shivaprasad S, Sivanandan H, Soman V, Lu X, Kakkar VV. Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy) Ldlr(tm1Her)/J mice. PLoS One. 2013;8:e58364.
107. Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol. 2007;50:2313-2318.
108. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholes-terolemic mice. Circulation. 2011;123:1083-1091.
109. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, Beau F, Yiotakis A, Newby AC, Dive V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2011;31:528-535.
110. Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol. 2010;8:102-113.
111. Rong JX, Blachford C, Feig JE, Bander I, Mayne J, Kusunoki J, Miller C, Davis M, Wilson M, Dehn S, Thorp E, Tabas I, Taubman MB, Rudel LL, Fisher EA. ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic tox-icity. Arterioscler Thromb Vasc Biol. 2013;33:4-12.
112. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese RV Jr. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001;107:163-171.
113. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfeld JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253-1263.
114. Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, Hotamisligil GS. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009;15:1383-1391.
115. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/-mice despite severe hypercholesterolemia. Atherosclerosis. 2008;198:39-48.
116. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of mac-rophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-715.
117. Brugaletta S, Gomez-Lara J, Garcia-Garcia HM, et al. Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging. 2012;28:1307-1314.
118. Lee IS, Bourantas CV, Muramatsu T, Gogas BD, Heo JH, Diletti R, Farooq V, Zhang Y, Onuma Y, Serruys PW, Garcia-Garcia HM. Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. Cardiovasc Ultrasound. 2013;11:25.
119. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205-215.
120. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar-dial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
121. Vucic E, Calcagno C, Dickson SD, et al. Regression of infammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. J Am Coll Cardiol Cardiovasc Imaging. 2012;5:819-828.
122. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808-818.
123. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024-1033.
124. Schutters K, Kusters DH, Chatrou ML, Montero-Melendez T, Donners M, Deckers NM, Krysko DV, Vandenabeele P, Perretti M, Schurgers LJ, Reutelingsperger C P. Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells. Cell Death Differ. 2013;20:49-56.
125. Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Cheung L, Fayad ZA, Langer R, Tabas I, Farokhzad OC. Development and in vivo effcacy of targeted polymeric infammation-resolving nanoparticles. Proc Natl Acad Sci USA. 2013;110:6506-6511.